Related Experiment Video
Updated: Jun 6, 2025
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased
Grigor Varuzhanyan1, Chia-Chun Chen2, Jack Freeland2,3
1Department of Microbiology Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095.
Abstract:
Adenocarcinomas from multiple tissues can converge to treatment-resistant small cell neuroendocrine (SCN) cancers composed of ASCL1, POU2F3, NEUROD1, and YAP1 subtypes. We investigated how mitochondrial metabolism influences SCN cancer (SCNC) progression. Extensive bioinformatics analyses encompassing thousands of patient tumors and human cancer cell lines uncovered enhanced expression of proliferator-activatedreceptor gamma coactivator 1-alpha (PGC-1α), a potent regulator of mitochondrial oxidative phosphorylation (OXPHOS), across several SCNCs. PGC-1α correlated tightly with increased expression of the lineage marker Achaete-scute homolog 1, (ASCL1) through a positive feedback mechanism. Analyses using a human prostate tissue-based SCN transformation system showed that the ASCL1 subtype has heightened PGC-1α expression and OXPHOS activity. PGC-1α inhibition diminished OXPHOS, reduced SCNC cell proliferation, and blocked SCN prostate tumor formation. Conversely, PGC-1α overexpression enhanced OXPHOS, validated by small-animal Positron Emission Tomography mitochondrial imaging, tripled the SCN prostate tumor formation rate, and promoted commitment to the ASCL1 lineage. These results establish PGC-1α as a driver of SCNC progression and subtype determination, highlighting metabolic vulnerabilities in SCNCs across different tissues.
Insights
Mitochondrial metabolism drives small cell neuroendocrine (SCN) cancer progression. PGC-1α (proliferator-activated receptor gamma coactivator 1-alpha) enhances oxidative phosphorylation, promoting SCNC growth and ASCL1 subtype determination.
Area of Science:
- Oncology
- Metabolic pathways
- Cancer subtypes
Background:
- Adenocarcinomas can transform into treatment-resistant small cell neuroendocrine (SCN) cancers.
- SCN cancers exhibit distinct subtypes, including ASCL1, POU2F3, NEUROD1, and YAP1.
- Mitochondrial metabolism's role in SCNC progression remains incompletely understood.
Purpose of the Study:
- To investigate the influence of mitochondrial metabolism on SCNC progression.
- To identify key metabolic regulators driving SCNC subtypes and growth.
Main Methods:
- Extensive bioinformatics analyses of patient tumors and cell lines.
- In vitro studies using a human prostate tissue-based SCN transformation system.
- Functional assays involving PGC-1α inhibition and overexpression, including PET imaging.
Main Results:
- Enhanced expression of proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and oxidative phosphorylation (OXPHOS) were observed in multiple SCNCs.
- PGC-1α positively correlated with ASCL1 lineage marker expression.
- PGC-1α inhibition reduced SCNC proliferation and tumor formation; PGC-1α overexpression enhanced these processes.
Conclusions:
- PGC-1α is a critical driver of SCNC progression and ASCL1 subtype determination.
- Targeting PGC-1α-mediated mitochondrial metabolism presents a potential therapeutic strategy for SCNCs across diverse tissues.
